<p><em>– 武田製藥重新獲得 XOMA Royalty 在 mezagitamab (TAK-079) 的大部分特許權收益 –</em></p>
<p><em>– XOMA Royalty 將有權根據與武田外部資產組合中九個開發階段資產相關的里程碑和特許權收益分享獲得付款 –</em></p>
<p>加利福尼亞州埃默裏維爾，2025 年 12 月 30 日（全球新聞通訊）-- XOMA Royalty Corporation（納斯達克：XOMA），這家生物技術特許權收益聚合公司，今天宣佈通過一項戰略特許權分享交易修訂了其與武田於 2006 年建立的合作關係。武田對 XOMA Royalty 與 mezagitamab 相關的特許權和里程碑付款義務將減少，XOMA Royalty 將根據一籃子九個開發階段資產獲得低至中單數字的特許權收益和里程碑付款，這些資產屬於武田的外部資產組合。</p>
<p>“我們繼續尋找通過創造性交易來擴展和多樣化我們的特許權和里程碑組合的方法，這對雙方都有利，” XOMA Royalty 首席投資官 Brad Sitko 表示。“武田和 XOMA Royalty 有着長期的合作歷史。通過修訂我們的合作關係，我們能夠將部分 mezagitamab 的經濟利益返還給武田，同時也擴展和多樣化 XOMA Royalty 在幾個有趣的早期和晚期項目中的投資組合。”</p>
<p><strong>Mezagitamab</strong></p>
<p>在修訂合作關係之前，XOMA Royalty 持有與 mezagitamab 相關的中單數字特許權和 1625 萬美元的潛在里程碑。未來，XOMA Royalty 將保留對 mezagitamab 的低單數字特許權收益權和最高 1300 萬美元的里程碑。</p>
<p><strong>武田外部資產組合中的開發階段資產</strong></p>
<p><strong>Osavampator</strong></p>
<ul>
<li><strong>Neurocrine Biosciences</strong> 正在開發 osavampator，這是一種潛在的首創研究性 α-氨基-3-羥基-5-甲基-4-異噁唑丙酸 (AMPA) 正向別構調節劑 (PAM)，用於對主要抑鬱症 (MDD) 治療反應不足的患者。</li>
</ul>
<p><strong>Volixibat</strong></p>
<ul>
<li><strong>Mirum Pharmaceuticals</strong> 正在開發 volixibat，這是一種最小吸收的口服給藥研究性療法，旨在選擇性抑制腸道膽鹽轉運蛋白 (IBAT)，用於原發性硬化性膽管炎 (PSC) 和原發性膽汁性膽管炎 (PBC)。</li>
</ul>
<p><strong>OHB-607 和五個早期階段的 Oak Hill Bio 資產</strong></p>
<ul>
<li><strong>Oak Hill Bio</strong> 及其合作伙伴正在開發 OHB-607，這是一種重組人 IGF-1/IGFBP-3，用於預防早產兒的支氣管肺發育不良。其他 Oak Hill Bio 資產有潛力產生特許權收益，涉及其他高未滿足需求或罕見疾病領域。</li>
</ul>
<p><strong>REC-4881</strong></p>
<ul>
<li><strong>Recursion Pharmaceuticals</strong> 正在開發 REC-4881，這是一種研究性 MEK1/2 抑制劑，用於家族性腺瘤性息肉病，這是一種影響美國、法國、德國、意大利、西班牙和英國約 50,000 人的罕見腫瘤易感綜合症。</li>
</ul>
<p><strong>關於 XOMA Royalty Corporation</strong></p>
<p>XOMA Royalty 是一家生物技術特許權收益聚合公司，在幫助生物技術公司實現改善人類健康目標方面發揮着獨特的作用。XOMA Royalty 收購與已授權給製藥或生物技術公司的預商業和商業治療候選藥物相關的潛在未來經濟利益。當 XOMA Royalty 收購未來經濟利益時，賣方將獲得非稀釋、無追索權的資金，可以用於推進其內部藥物候選者或用於一般企業目的。XOMA Royalty 擁有廣泛且不斷增長的資產組合（資產定義為獲得與基礎治療候選者的推進相關的潛在未來經濟利益的權利）。有關 XOMA Royalty 及其投資組合的更多信息，請訪問 www.xoma.com 或在 LinkedIn 上關注 XOMA Royalty Corporation。</p>
<p><strong>XOMA Royalty 前瞻性聲明/説明性備註</strong></p>
<p>本新聞稿中包含的某些聲明是根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條的定義的前瞻性聲明，包括關於潛在商業和里程碑付款的時間和金額，以及與 mezagitamab、osavampator、volixibat、OHB-607 和 Oak Hill Bio 資產以及 REC-4881 相關的其他發展。在某些情況下，您可以通過諸如 “預期”、“打算”、“相信”、“估計”、“計劃”、“尋求”、“預測”、“期望”、“可能”、“將”、“會”、“可以” 或 “應該” 等術語或這些術語的否定形式或類似表達來識別這些前瞻性聲明。這些前瞻性聲明並不能保證 XOMA Royalty 的表現，您不應對這些聲明過於依賴。這些聲明基於可能不準確的假設，實際結果可能因生物技術行業固有的某些風險而與預期有重大差異，包括與我們的產品候選者仍在開發中相關的事實，以及我們的許可方可能需要大量資金以繼續開發，而這些資金可能不可用；我們不知道我們擁有所有權或特許權的產品是否會有或將繼續有可行的市場；如果我們擁有特許權的治療產品候選者未獲得監管批准，我們的第三方許可方將無法將其推向市場。XOMA Royalty 滿足這些期望的其他潛在風險在 XOMA Royalty 最近提交的 10-Q 表格和其他向證券交易委員會提交的文件中有更詳細的描述。在考慮 XOMA Royalty 的前景時，請仔細考慮這些風險。本新聞稿中的任何前瞻性聲明僅代表 XOMA Royalty 在本新聞稿日期的信念和假設，不應被視為其在任何後續日期的觀點。XOMA Royalty 不承擔更新任何前瞻性聲明的義務，除非法律要求。</p>
<p>説明性備註：本新聞稿中提到的 “投資組合” 僅指與一系列正在開發的藥品相關的里程碑和/或特許權權益。 本新聞稿中提到的 “資產” 僅指與單個正在開發的藥品相關的里程碑和/或特許權權益。</p>
<p>截至本新聞稿日期，XOMA Royalty 的里程碑和特許權投資組合中的商業資產包括 VABYSMO®（faricimab-svoa）、OJEMDA™（tovorafenib）、MIPLYFFA™（arimoclomol）、XACIATO™（克林黴素磷酸鹽）陰道凝膠 2%、IXINITY® [凝血因子 IX（重組）] 和 DSUVIA®（舌下用舒芬太尼片）。投資組合中的所有其他資產均為研究性化合物。尚未確定其療效和安全性。沒有保證任何研究性化合物會商業化。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>XOMA Royalty 投資者聯繫：</strong></td>
<td><strong>XOMA Royalty 媒體聯繫：</strong></td>
</tr>
<tr>
<td>Juliane Snowden</td>
<td>Kathy Vincent</td>
</tr>
<tr>
<td>XOMA Royalty Corporation</td>
<td>KV Consulting &amp; Management</td>
</tr>
<tr>
<td>+1-646-438-9754</td>
<td>kathy@kathyvincent.com</td>
</tr>
<tr>
<td>juliane.snowden@xoma.com</td>
<td></td>
</tr>
</tbody>
</table>
<hr/>
<p>1 https://ir.recursion.com/news-releases/news-release-details/preliminary-phase-1b2-data-rec-4881-familial-adenomatous</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQTJPQ00zTXpNNU1qUTVJekl3TWpjd01UWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQTJPQ00zTXpNNU1qUTVJekl3TWpjd01UWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmUzM2ZlNzEtOTgzYy00YjFmLWI5MmItODMyZTkyZTdjMmRlLTEwMzg3NTMtMjAyNS0xMi0zMC1lbg==/tiny/XOMA-Royalty-Corporation.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmUzM2ZlNzEtOTgzYy00YjFmLWI5MmItODMyZTkyZTdjMmRlLTEwMzg3NTMtMjAyNS0xMi0zMC1lbg==/tiny/XOMA-Royalty-Corporation.png"/></p>

標記臨牀研究

<p>XOMA Royalty Corporation 已修訂與武田製藥的合作協議，重新獲得 mezagitamab 的多數特許權利益。XOMA 現在將從武田的九個開發階段資產中獲得低至中個位數的特許權使用費和里程碑付款。這些變更減少了武田的付款義務，同時使 XOMA 的特許權使用費組合更加多樣化。XOMA 將保留 mezagitamab 的低個位數特許權使用費和高達 1300 萬美元的里程碑付款。這一戰略交易旨在使雙方受益，並增強 XOMA 的資產組合</p>

<p><em>– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –</em></p>
<div class="lb-trans"><p><em>– 武田製藥重新獲得 XOMA Royalty 在 mezagitamab (TAK-079) 的大部分特許權收益 –</em></p>
</div><p><em>– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s externalized assets portfolio –</em></p>
<div class="lb-trans"><p><em>– XOMA Royalty 將有權根據與武田外部資產組合中九個開發階段資產相關的里程碑和特許權收益分享獲得付款 –</em></p>
</div><p>EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Takeda through a strategic royalty share transaction. Takeda’s royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced, and XOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of nine development-stage assets that are held within Takeda’s externalized assets portfolio.</p>
<div class="lb-trans"><p>加利福尼亞州埃默裏維爾，2025 年 12 月 30 日（全球新聞通訊）-- XOMA Royalty Corporation（納斯達克：XOMA），這家生物技術特許權收益聚合公司，今天宣佈通過一項戰略特許權分享交易修訂了其與武田於 2006 年建立的合作關係。武田對 XOMA Royalty 與 mezagitamab 相關的特許權和里程碑付款義務將減少，XOMA Royalty 將根據一籃子九個開發階段資產獲得低至中單數字的特許權收益和里程碑付款，這些資產屬於武田的外部資產組合。</p>
</div><p>“We continue to find ways to expand and diversify our royalty and milestone portfolio through creative transactions that are beneficial to both parties,” stated Brad Sitko, Chief Investment Officer of XOMA Royalty. “Takeda and XOMA Royalty have a long history of collaboration. By amending our collaboration, we are able to return a portion of our mezagitamab economics to Takeda, while also expanding and diversifying XOMA Royalty’s portfolio across several interesting early- and late-stage programs.”</p>
<div class="lb-trans"><p>“我們繼續尋找通過創造性交易來擴展和多樣化我們的特許權和里程碑組合的方法，這對雙方都有利，” XOMA Royalty 首席投資官 Brad Sitko 表示。“武田和 XOMA Royalty 有着長期的合作歷史。通過修訂我們的合作關係，我們能夠將部分 mezagitamab 的經濟利益返還給武田，同時也擴展和多樣化 XOMA Royalty 在幾個有趣的早期和晚期項目中的投資組合。”</p>
</div><p><strong>Mezagitamab</strong></p>
<div class="lb-trans"><p><strong>Mezagitamab</strong></p>
</div><p>Prior to amending the collaboration, XOMA Royalty held a mid-single digit royalty and $16.25 million in potential milestones associated with mezagitamab. Going forward, XOMA Royalty will retain a low single-digit royalty entitlement on mezagitamab and up to $13.0 million in milestones.</p>
<div class="lb-trans"><p>在修訂合作關係之前，XOMA Royalty 持有與 mezagitamab 相關的中單數字特許權和 1625 萬美元的潛在里程碑。未來，XOMA Royalty 將保留對 mezagitamab 的低單數字特許權收益權和最高 1300 萬美元的里程碑。</p>
</div><p><strong>Development-Stage Assets from Takeda’s Externalized Assets Portfolio</strong></p>
<div class="lb-trans"><p><strong>武田外部資產組合中的開發階段資產</strong></p>
</div><p><strong>Osavampator</strong></p>
<div class="lb-trans"><p><strong>Osavampator</strong></p>
</div><ul>
<li><strong>Neurocrine Biosciences</strong> is developing osavampator, a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) for patients who have inadequate response to treatment for major depressive disorder (MDD).</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Neurocrine Biosciences</strong> 正在開發 osavampator，這是一種潛在的首創研究性 α-氨基-3-羥基-5-甲基-4-異噁唑丙酸 (AMPA) 正向別構調節劑 (PAM)，用於對主要抑鬱症 (MDD) 治療反應不足的患者。</li>
</ul>
</div><p><strong>Volixibat</strong></p>
<div class="lb-trans"><p><strong>Volixibat</strong></p>
</div><ul>
<li><strong>Mirum Pharmaceuticals</strong> is developing volixibat, a minimally absorbed, orally administered investigational therapy designed to selectively inhibit ileal bile acid transporter (IBAT), for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Mirum Pharmaceuticals</strong> 正在開發 volixibat，這是一種最小吸收的口服給藥研究性療法，旨在選擇性抑制腸道膽鹽轉運蛋白 (IBAT)，用於原發性硬化性膽管炎 (PSC) 和原發性膽汁性膽管炎 (PBC)。</li>
</ul>
</div><p><strong>OHB-607 and five early-stage Oak Hill Bio assets</strong></p>
<div class="lb-trans"><p><strong>OHB-607 和五個早期階段的 Oak Hill Bio 資產</strong></p>
</div><ul>
<li><strong>Oak Hill Bio</strong> and their partner are developing OHB-607, a recombinant human IGF-1/IGFBP-3 for the prevention of bronchopulmonary dysplasia in premature infants. Additional Oak Hill Bio assets that have the potential to generate royalties address other high unmet need or rare disease areas.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Oak Hill Bio</strong> 及其合作伙伴正在開發 OHB-607，這是一種重組人 IGF-1/IGFBP-3，用於預防早產兒的支氣管肺發育不良。其他 Oak Hill Bio 資產有潛力產生特許權收益，涉及其他高未滿足需求或罕見疾病領域。</li>
</ul>
</div><p><strong>REC-4881</strong></p>
<div class="lb-trans"><p><strong>REC-4881</strong></p>
</div><ul>
<li><strong>Recursion Pharmaceuticals</strong> is developing REC-4881, an investigational MEK1/2 inhibitor for familial adenomatous polyposis, a rare tumor predisposition syndrome affecting approximately 50,000 people in the U.S., France, Germany, Italy, Spain, and the UK1.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Recursion Pharmaceuticals</strong> 正在開發 REC-4881，這是一種研究性 MEK1/2 抑制劑，用於家族性腺瘤性息肉病，這是一種影響美國、法國、德國、意大利、西班牙和英國約 50,000 人的罕見腫瘤易感綜合症。</li>
</ul>
</div><p><strong>About XOMA Royalty Corporation</strong></p>
<div class="lb-trans"><p><strong>關於 XOMA Royalty Corporation</strong></p>
</div><p>XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the sellers receive non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.</p>
<div class="lb-trans"><p>XOMA Royalty 是一家生物技術特許權收益聚合公司，在幫助生物技術公司實現改善人類健康目標方面發揮着獨特的作用。XOMA Royalty 收購與已授權給製藥或生物技術公司的預商業和商業治療候選藥物相關的潛在未來經濟利益。當 XOMA Royalty 收購未來經濟利益時，賣方將獲得非稀釋、無追索權的資金，可以用於推進其內部藥物候選者或用於一般企業目的。XOMA Royalty 擁有廣泛且不斷增長的資產組合（資產定義為獲得與基礎治療候選者的推進相關的潛在未來經濟利益的權利）。有關 XOMA Royalty 及其投資組合的更多信息，請訪問 www.xoma.com 或在 LinkedIn 上關注 XOMA Royalty Corporation。</p>
</div><p><strong>XOMA Royalty Forward-Looking Statements/Explanatory Notes</strong></p>
<div class="lb-trans"><p><strong>XOMA Royalty 前瞻性聲明/説明性備註</strong></p>
</div><p>Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial and milestone payments to XOMA Royalty and other developments related to mezagitamab, osavampator, volixibat, OHB-607 and the Oak Hill Bio assets, and REC-4881. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; and if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.</p>
<div class="lb-trans"><p>本新聞稿中包含的某些聲明是根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條的定義的前瞻性聲明，包括關於潛在商業和里程碑付款的時間和金額，以及與 mezagitamab、osavampator、volixibat、OHB-607 和 Oak Hill Bio 資產以及 REC-4881 相關的其他發展。在某些情況下，您可以通過諸如 “預期”、“打算”、“相信”、“估計”、“計劃”、“尋求”、“預測”、“期望”、“可能”、“將”、“會”、“可以” 或 “應該” 等術語或這些術語的否定形式或類似表達來識別這些前瞻性聲明。這些前瞻性聲明並不能保證 XOMA Royalty 的表現，您不應對這些聲明過於依賴。這些聲明基於可能不準確的假設，實際結果可能因生物技術行業固有的某些風險而與預期有重大差異，包括與我們的產品候選者仍在開發中相關的事實，以及我們的許可方可能需要大量資金以繼續開發，而這些資金可能不可用；我們不知道我們擁有所有權或特許權的產品是否會有或將繼續有可行的市場；如果我們擁有特許權的治療產品候選者未獲得監管批准，我們的第三方許可方將無法將其推向市場。XOMA Royalty 滿足這些期望的其他潛在風險在 XOMA Royalty 最近提交的 10-Q 表格和其他向證券交易委員會提交的文件中有更詳細的描述。在考慮 XOMA Royalty 的前景時，請仔細考慮這些風險。本新聞稿中的任何前瞻性聲明僅代表 XOMA Royalty 在本新聞稿日期的信念和假設，不應被視為其在任何後續日期的觀點。XOMA Royalty 不承擔更新任何前瞻性聲明的義務，除非法律要求。</p>
</div><p>EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.</p>
<div class="lb-trans"><p>説明性備註：本新聞稿中提到的 “投資組合” 僅指與一系列正在開發的藥品相關的里程碑和/或特許權權益。 本新聞稿中提到的 “資產” 僅指與單個正在開發的藥品相關的里程碑和/或特許權權益。</p>
</div><p>As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.</p>
<div class="lb-trans"><p>截至本新聞稿日期，XOMA Royalty 的里程碑和特許權投資組合中的商業資產包括 VABYSMO®（faricimab-svoa）、OJEMDA™（tovorafenib）、MIPLYFFA™（arimoclomol）、XACIATO™（克林黴素磷酸鹽）陰道凝膠 2%、IXINITY® [凝血因子 IX（重組）] 和 DSUVIA®（舌下用舒芬太尼片）。投資組合中的所有其他資產均為研究性化合物。尚未確定其療效和安全性。沒有保證任何研究性化合物會商業化。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>XOMA Royalty Investor Contact:</strong></td>
<td><strong>XOMA Royalty Media Contact:</strong></td>
</tr>
<tr>
<td>Juliane Snowden</td>
<td>Kathy Vincent</td>
</tr>
<tr>
<td>XOMA Royalty Corporation</td>
<td>KV Consulting &amp; Management</td>
</tr>
<tr>
<td>+1-646-438-9754</td>
<td>kathy@kathyvincent.com</td>
</tr>
<tr>
<td>juliane.snowden@xoma.com</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>XOMA Royalty 投資者聯繫：</strong></td>
<td><strong>XOMA Royalty 媒體聯繫：</strong></td>
</tr>
<tr>
<td>Juliane Snowden</td>
<td>Kathy Vincent</td>
</tr>
<tr>
<td>XOMA Royalty Corporation</td>
<td>KV Consulting &amp; Management</td>
</tr>
<tr>
<td>+1-646-438-9754</td>
<td>kathy@kathyvincent.com</td>
</tr>
<tr>
<td>juliane.snowden@xoma.com</td>
<td></td>
</tr>
</tbody>
</table>
</div><hr/>
<div class="lb-trans"><hr/>
</div><p>1 https://ir.recursion.com/news-releases/news-release-details/preliminary-phase-1b2-data-rec-4881-familial-adenomatous</p>
<div class="lb-trans"><p>1 https://ir.recursion.com/news-releases/news-release-details/preliminary-phase-1b2-data-rec-4881-familial-adenomatous</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQTJPQ00zTXpNNU1qUTVJekl3TWpjd01UWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODA2OCM3MzM5MjQ5IzIwMjcwMTY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmUzM2ZlNzEtOTgzYy00YjFmLWI5MmItODMyZTkyZTdjMmRlLTEwMzg3NTMtMjAyNS0xMi0zMC1lbg==/tiny/XOMA-Royalty-Corporation.png" alt="" original-src="https://ml.globenewswire.com/media/ZmUzM2ZlNzEtOTgzYy00YjFmLWI5MmItODMyZTkyZTdjMmRlLTEwMzg3NTMtMjAyNS0xMi0zMC1lbg==/tiny/XOMA-Royalty-Corporation.png"/></p>

標記臨牀研究和武田執行戰略特許權使用費共享交易，並修改現有的 Mezagitamab 協議 | XOMA 股票新聞